Bal Pharma Clarifies 18-Month Preferential Proceeds Timeline

Date: August 25, 2026

Board Meeting Outcomes

• The company clarifies that the timeline for utilization of net proceeds/tenure of the Convertible Warrants is 18 months from the date of allotment
• This timeline is in accordance with Regulation 162 of the SEBI (Issue of Capital and Disclosure Requirements) Regulations, 2018
• The utilization is subject to receipt of requisite in-principle approval from the Stock Exchanges
• Confirms there is no change in the objects of the Preferential Issue or the manner of utilization of the proceeds

Other Operational / Legal / Strategic Disclosures

• The present intimation is specifically made to clarify the tentative timeline for utilization of net proceeds
• The clarification is provided in view of the 18-month tenure of the Convertible Warrants